NCT06291025View on ClinicalTrials.gov

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study

NANot yet recruitingINTERVENTIONAL

Enrollment

131

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2026

Conditions

Thrombotic Microangiopathies

Interventions

PROCEDURE

PEX-FREE

The study/experimental procedure consists in replacing daily PEX with daily plasma infusions (ie. Quarantine fresh frozen plasma (PFC-Se), solvent detergent/viral inactivated plasma (PFC-SD = OCTAPLASLG) or amotosalen-inactivated plasma (PFC-IA); volume 15mL/kg/day).

All Listed Sponsors

lead

University Hospital, Rouen

OTHER

NCT06291025 - Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura: Multicentric Non-inferiority Single-arm Study | Biotech Hunter | Biotech Hunter